Journal article

Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial

Greg J Fox, Cam Binh Nguyen, Thu Anh Nguyen, Phuong Thuy Tran, Ben J Marais, Steve M Graham, Binh Hoa Nguyen, Kavi Velen, David W Dowdy, Paul Mason, Warwick J Britton, Marcel A Behr, Andrea Benedetti, Dick Menzies, Viet Nhung Nguyen, Guy B Marks

BMJ Open | BMJ PUBLISHING GROUP | Published : 2020

Abstract

INTRODUCTION: Treatment of latent tuberculosis infection (LTBI) plays a substantial role in the prevention of drug-susceptible tuberculosis (TB). However, clinical trials to evaluate the efficacy of preventive therapy for presumed multidrug-resistant (MDR) LTBI are lacking. This trial aims to evaluate the efficacy of the antibiotic levofloxacin in preventing the development of active TB among latently infected contacts of index patients with MDR-TB. METHODS AND ANALYSIS: A double-blind placebo-controlled parallel group randomised controlled trial will be conducted in 10 provinces of Vietnam. Household contacts living with patients with bacteriologically confirmed rifampicin-resistant or MDR-..

View full abstract

Grants

Awarded by Australian National Health and Medical Research Council (NHMRC)


Awarded by NHMRC CJ Martin Fellowship


Awarded by NHMRC Career Development Fellowship


Funding Acknowledgements

This work is supported by the Australian National Health and Medical Research Council (NHMRC) grant application number 1081443. GJF was supported by a NHMRC CJ Martin Fellowship (APP 1054107) and NHMRC Career Development Fellowship (APP 1148372). The trial sponsor is the Woolcock Institute of Medical Research, 431 Glebe Point Road, Glebe, NSW Australia, 2037.